A Southwest Oncology Group phase II evaluation of fluderabine monophosphate in sarcoma.
Grever
M R
MR
National Cancer Institute, Bethesda, MD.
Benedetti
J
J
Balcerzak
S P
SP
Taylor
S A
SA
Miller
T P
TP
Dakhil
S R
SR
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000188:drug therapy*; D012894:Sleep Stages; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate